Cancer drug resistance in multiple myeloma

References

[1] Uckun FM,Demirer T.Contemporary patient-tailored treatment strategies against high risk and relapsed or refractory multiple myeloma.EBioMedicine2019;39:612-20 PMCID:PMC6354702

[2] Minnie SA.Immunotherapy of multiple myeloma.J Clin Invest2020;130:1565-75 PMCID:PMC7108923

[3] Martínez-martín S.MYC inhibitors in multiple myeloma.Cancer Drug Resist2021;4:842-65 PMCID:PMC3789166

[4] Uckun FM.Overcoming the Immunosuppressive tumor microenvironment in multiple myeloma.Cancers (Basel)2021;13:2018 PMCID:PMC8122391

[5] Voorhees PM,Laubach J.Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial.Blood2020;136:936-45 PMCID:PMC7441167

[6] Topp MS,Zugmaier G.Anti-B-cell maturation antigen BiTE molecule AMG 420 induces responses in multiple myeloma.J Clin Oncol2020;38:775-83

[7] Fayon M,Abecassis A.Bi38-3 is a novel CD38/CD3 bispecific T-cell engager with low toxicity for the treatment of multiple myeloma.Haematologica2021;106:1193-7 PMCID:PMC8018129

[8] Alhallak K,Jeske A.Bispecific T cell engagers for the treatment of multiple myeloma: achievements and challenges.Cancers (Basel)2021;13:2853 PMCID:PMC8228067

[9] Berdeja JG,Usmani SZ.Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.Lancet2021;398:314-24

[10] Usmani SZ,van de Donk NWCJ.Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study.Lancet2021;398:665-74

[11] Berdeja JG,Oriol A.Updated results of a phase 1, first-in-human study of talquetamab, a G protein-coupled receptor family C group 5 member D (GPRC5D) × CD3 bispecific antibody, in relapsed/refractory multiple myeloma (MM).J Clin Oncol2021;39:8008

[12] Gozzetti A,Sicuranza A.Drug resistance and minimal residual disease in multiple myeloma.Cancer Drug Resist2022;5:171-83

[13] Moscvin M,Bianchi G.Overcoming drug resistance by targeting protein homeostasis in multiple myeloma.Cancer Drug Resist2021;4:1028-46 PMCID:PMC8903187

[14] Black H.Gene expression profiling as a prognostic tool in multiple myeloma.Cancer Drug Resist2021;4:1008-18

[15] Giannoni P.The HGF/c-MET axis as a potential target to overcome survival signals and improve therapeutic efficacy in multiple myeloma.Cancer Drug Resist2021;4:923-33

[16] Pinto V,Caires HR,Guimarães JE.Multiple myeloma: available therapies and causes of drug resistance.Cancers (Basel)2020;12:407 PMCID:PMC7072128

[17] Mynott RL.Drug and solute transporters in mediating resistance to novel therapeutics in multiple myeloma.ACS Pharmacol Transl Sci2021;4:1050-65 PMCID:PMC8204322

[18] Mynott RL.Inhibition of P-glycoprotein does not increase the efficacy of proteasome inhibitors in multiple myeloma cells.ACS Pharmacol Transl Sci2021;4:713-29 PMCID:PMC8033612

[19] Gandhi UH,Lakshman A.Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy.Leukemia2019;33:2266-75 PMCID:PMC6820050

[20] Moreau P,San Miguel J.Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group.Lancet Oncol2021;22:e105-18

[21] Davis LN.Emerging therapeutic strategies to overcome drug resistance in multiple myeloma.Cancers (Basel)2021;13:1686 PMCID:PMC8038312

[22] Haertle L,Munawar U.Cereblon enhancer methylation and IMiD resistance in multiple myeloma.Blood2021;138:1721-6 PMCID:PMC8569411

[23] Wallington-Beddoe CT,Kuss BJ.Resistance to proteasome inhibitors and other targeted therapies in myeloma.Br J Haematol2018;182:11-28

[24] Barrio S,Da-Viá M.Spectrum and functional validation of PSMB5 mutations in multiple myeloma.Leukemia2019;33:447-56

[25] Puła A,Robak T.MicroRNA in multiple myeloma - a role in pathogenesis and prognostic significance.Curr Med Chem2021;28:6753-72

[26] Muz B,King J.Targeting CD47 As a novel therapeutic strategy in multiple myeloma.Blood2017;130:3099

[27] Kim D,Willingham SB,Wernig G.Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells.Leukemia2012;26:2538-45

[28] Rastgoo N,Liu A.Targeting CD47/TNFAIP8 by miR-155 overcomes drug resistance and inhibits tumor growth through induction of phagocytosis and apoptosis in multiple myeloma.Haematologica2020;105:2813-23 PMCID:PMC7716364

[29] Chen H,Chen J.miR-218 contributes to drug resistance in multiple myeloma via targeting LRRC28.J Cell Biochem2021;122:305-14

[30] Wang Q,Xian M.MIF as a biomarker and therapeutic target for overcoming resistance to proteasome inhibitors in human myeloma.Blood2020;136:2557-73 PMCID:PMC7714094

[31] Bajpai R,Wei C.Targeting glutamine metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to venetoclax.Oncogene2016;35:3955-64 PMCID:PMC5025767

[32] Lagadinou ED,Callahan K.BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells.Cell Stem Cell2013;12:329-41 PMCID:PMC3595363

[33] Jones CL,D’Alessandro A.Inhibition of amino acid metabolism selectively targets human leukemia stem cells.Cancer Cell2018;34:724-40.e4 PMCID:PMC6280965

[34] Kumar S,Gasparetto C.Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma.Blood2017;130:2401-9

[35] Kumar SK,Cavo M.Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial.Lancet Oncol2020;21:1630-42

[36] Bolomsky A,Malyutina A.Heterogeneous modulation of Bcl-2 family members and drug efflux mediate MCL-1 inhibitor resistance in multiple myeloma.Blood Adv2021;5:4125-39

[37] Cohen YC,Wang SY.Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing.Nat Med2021;27:491-503

[38] Goicoechea I,Cedena MT.Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma.Blood2021;137:49-60

[39] Sherbenou DW,Behrens CR.Potent activity of an anti-ICAM1 antibody-drug conjugate against multiple myeloma.Clin Cancer Res2020;26:6028-38 PMCID:PMC7669584

[40] Uckun FM.Dual targeting of multiple myeloma stem cells and myeloid-derived suppressor cells for treatment of chemotherapy-resistant multiple myeloma.Front Oncol2021;11:760382 PMCID:PMC8631522

[41] Fontana F,Allen JS.VLA4-targeted nanoparticles hijack cell adhesion-mediated drug resistance to target refractory myeloma cells and prolong survival.Clin Cancer Res2021;27:1974-86 PMCID:PMC8026499

[42] Byrgazov K,Besse A.Up-regulation of multidrug resistance protein MDR1/ABCB1 in carfilzomib-resistant multiple myeloma differentially affects efficacy of anti-myeloma drugs.Leuk Res2021;101:106499

[43] Chari A,Gavriatopoulou M.Oral Selinexor-dexamethasone for triple-class refractory multiple myeloma.N Engl J Med2019;381:727-38

[44] Innao V,Allegra AG,Allegra A.Promising anti-mitochondrial agents for overcoming acquired drug resistance in multiple myeloma.Cells2021;10:439 PMCID:PMC7922387

[45] Federico C,Sun J.Tumor microenvironment-targeted nanoparticles loaded with bortezomib and ROCK inhibitor improve efficacy in multiple myeloma.Nat Commun2020;11:6037 PMCID:PMC7699624